Rhabdomyosarcoma

Animal Models for Cancer

Cancer is a complex multifactorial disease that affects many people worldwide. Animal models play an important role in deciphering cancer biology and developing new therapies. The animal models widely used in cancer research include tumor xenografts, genetically engineered mice, chemically induced models, and spontaneous tumor models. These models provide a controlled environment to study cancer progression, the interaction of cancer and the immune system, and the effectiveness of new therapies. Although animal models have several advantages, it is important to identify their limitations and use them in conjunction with other preclinical models, such as in-vitro cell culture and patient-derived xenografts, to ensure that results are transferable to humans. In this chapter, we discuss the importance of animal models in cancer research, the different types of animal models, and their advantages and disadvantages. We also provide some examples of animal models used in cancer research. Collectively, animal models have been invaluable in advancing our understanding of cancer and will continue to be important tools in the development of new therapies.

References

Application of Main Group Elements and Their Compounds in Medicine

Pharmaceutical Potential of Pyrimidines as Antiviral Agents

Antiviral drugs are a class of medicines particularly used for the treatment of viral infections. Drugs that combat viral infections are called antiviral drugs. Viruses are among the major pathogenic agents that cause a number of serious diseases in humans, animals and plants. Viruses cause many diseases in humans, from self-resolving diseases to acute fatal diseases. The strategies for the development of antiviral drugs are generally focused on two different approaches, i.e., targeting the viruses themselves or the host cell factors. Antiviral drugs that directly target viruses include the inhibitors of virus attachment, inhibitors of virus entry, uncoating inhibitors, polymerase inhibitors, protease inhibitors, nucleotide reverse transcriptase, inhibitors of nucleoside and the inhibitors of integrase. The inhibitors of protease (ritonavir, atazanavir and darunavir), viral DNA polymerase (acyclovir, tenofovir, valganciclovir and valacyclovir) and integrase (raltegravir) are listed among the top 200 drugs by sales during the2010. Still, there are no effective antiviral drugs available for many viral infections. There is a couple of drugs for herpes viruses, many for influenza and some new antiviral drugs for treating hepatitis C infection and HIV. This chapter gives an overview of the pyrimidines and hetero annulated pyrimidines that have been reported to be active against viral infections; identification of novel pyrimidine leads may be used in the designing of new potent, selective and less toxic novel therapeutic agents having promising antiviral activity. An effort has been made to compile all the possible information regarding antiviral pyrimidines and bring them together to make easy availability of the existing literature on the subject. The objective of this chapter is to provide the structural and antiviral activity information as well as methods being used for the screening of the antiviral activity and antiviral potential IC50/ED50/CC50 values of the reported active pyrimidines are briefly discussed.

Chromosome X

X Chromosome is the sex chromosome that is found in many organisms. Both males and females, including mammalians, have X Chromosomes. Females have XX sets of chromosomes, and males have XY sets of chromosomes. X Chromosome aids in identifying the sex of the organism. The Human X chromosome contains approximately 1500 genes. These genes may undergo some genetic alterations and eventually lead to complex diseases. Genetic mutations in some of the genes of the X chromosome are associated with cancer. Some specific mutations are observed in human cancer cells. This chapter specifically relayed on X chromosomal genes that are associated with different types of cancer and gave information on the location of the gene in the X chromosome. Moreover, the function of the specific gene and information regarding how many types of cancers were associated with a particular gene, has also been provided.

Chromosome 15

The genomic alteration at chromosome 15 has been widely recognized as the utmost significant and prevalent alteration in several cancers, including non-small-cell lung cancer, breast cancer, ovarian cancer, prostate cancer, gastrointestinal cancer, acute lymphoblastic leukemia, colorectal carcinoma, hepatocellular carcinoma, myeloma, pituitary adenomas, etc. Emerging reports suggest that the abnormalities of prime genes in chromosome 15 have drastic effects on tumor development and progression, and can be candidate biomarkers of disease prognosis, disease progression, and response to treatment. The translocations involving chromosome 15 and other chromosomes have been found in tumors, including mucoepidermoid carcinomas, mixed-lineage leukemia, colorectal cancer, pancreatic cancer, sarcoma, lung adenocarcinoma, melanoma, brain cancer, cholangiocarcinoma, spitz tumor, congenital mesoblastic nephroma, papillary thyroid cancer, pontine glioma tumors, and acute promyelocytic leukemia. The tumor suppressor genes such as C15orf65, CSK, CRABP1, DAPK2, FES, GREM1, KNSTRN, NEDD4-1, NTRK3, PML, SPRED1, TPM1, and TCF12 under chromosome 15 play a crucial role by enhancing cellular growth, proliferation, migration, invasion, metastasis, cellular differentiation, and development in various cancer, including colorectal cancer, acute promyelocytic leukemia, myeloid leukemia, breast cancer, thyroid carcinoma, glioblastoma, intrahepatic cholangiocarcinoma, chondrosarcoma, cartilaginous cancer, Squamous cell carcinoma, non- small-cell lung carcinomas, mucosal melanoma, and oral squamous cell carcinoma. Chapter 15 discusses the significance of each important gene under chromosome 15 in mediating oncogenesis. The elevated or attenuated expression levels of these cardinal genes can either act as an oncogene or a tumor suppressor. Thus, shedding light on these genes would be a game changer in the field of cancer genetics and theragnostic.

Chromosome 14

Cancer genetics has focused on several mutational events within a tumor cell for many years. Recently, the study on cancer genetics has been widened by concentrating on the importance of intercellular communication and epigenetic events causing tumor progression and development. The translocation of genetic material betwixt chromosome 14 and other chromosomes may engender the formation of various types of tumors. Recent studies emphasize that these chief translocations between two chromosomes may disrupt the genes crucial for controlling cell growth and cell division. The translocations involving chromosome-14 and other chromosomes have been found in tumors including acute myeloid Leukemia, acute lymphoblastic leukemia, acute bilineal leukemia, follicular lymphoma, small cell lung cancer, non-Hodgkin’s lymphoma, Burkitt lymphoma and multiple myeloma. The tumor suppressor genes, such as ARID4A, ARID4B, BCL11B, BMP4, CCNB1IP1, CEBPE, DICER1, DLK1, ESR2, FOXN3, HIF1A, MAX, MEG3, NDRG2 and TTF-1/NKX2-1 under chromosome 14, play a hypercritical role by enhancing cellular differentiation, migration, proliferation, metastasis, invasion, cellular growth, and development in several tumors, including breast cancer, pancreatic tumor, osteosarcoma, lung cancer, endocrine tumor, T-ALL, cystic nephroma, Hodgkin lymphoma, pleuropulmonary blastomas, Sertoli Leydig ovarian tumors and rhabdomyosarcoma. Chapter 14 meticulously discusses the importance of each predominant gene under chromosome 14 in mediating tumorigenesis. In cancer genetics, these cardinal genes play a crucial role by acting as an oncogene or a tumor suppressor in several cancers. Thus, targeting these tumor-causing genes would provide a breakthrough in cancer biology and oncology when concerned with future perspectives.

Chromosome 13

Chromosome 13 represents around 4 percent of the total cellular DNA with 115 million base pairs. It is home to various tumor suppressors and oncogenes, such as ADP ribosylation factors like GTPase-11 (ARL11), Retinoblastoma-1 (RB1), Ras-related protein Rap-2a (RAP2A), etc. Most of the somatic mutations in this chromosome lead to cancer development. Further, deletion in this chromosome has been reported to support the cancer of leukemias, lymphomas, etc. In this chapter, we have tried to list cancer-causing genes and their possible oncogenesis in cancer development.

Overview of Cancer

The characteristics of cancer cells are continuous cell growth due to their non-responding nature to the signals of stopping the growth or apoptosis, the ability to spread in other parts of the body, and immortality of cells because of their capacity to restore their telomeres. The clinical features depend on the size and location of cancer and the presence or absence of metastasis. Local and systemic symptoms rely on the tumor mass and the body’s response to cancer, respectively. Cancer is classified according to the tissue involved, like Carcinomas, Sarcomas, Myeloma, Leukemia, Lymphoma, Germ cell tumor, and blastoma. The globally recognized standard to classify the extent of cancer spread is called T.N.M. Classification. It applies to many solid tumor cancers but is not relevant to leukemia and the central nervous systems tumor. The tumor can be diagnosed with tests like mammograms, Pap smears, Tumor markers, Bone scans, MRI, Tissue biopsies, and PET-CT scans. The treatment depends on the type and stage of cancer and the patient's overall health. Common treatment modalities are surgery, radiation, and chemotherapy. Other treatments are targeted/biological therapies, hematopoietic stem cell transplants, angiogenesis inhibitors, cryosurgery, and photodynamic therapy. Every treatment has its risks, benefits, and side effects.

Chromosome 11

Over the years, many scientists and doctors have been treating the deadly cancer disease but cannot find a permanent treatment for this disease. Also, sometimes it becomes tough to understand the mechanisms and causes of cancer as it is a very complex disease that involves many biological processes. Due to the redundancy in our biological system, cancer progression becomes very easy, thus making it difficult to cure. To find the root cause of this disease, we should know what genetic alterations are causing cancer progress and who is participating in these alterations, like proteins, signaling pathways, or genes. Cancer is caused due to various reasons; it can be due to genetics but primarily due to carcinogens, causing mutations in the genes, thereby making them an oncogene. The Proto-oncogenes are those genes that usually assist the growth of tumor cells. The alteration, mutation, or increased copy number of a particular gene may turn into a proto-oncogene, which could end up completely activated or turned on. Many Tumor-causing alterations or mutations related to oncogenes are usually acquired and not inherited. These tumor-causing mutations often actuate oncogenes via chromosomal rearrangement or changes in the chromosome, which sequestrates one gene after another, thereby permitting the first gene to prompt the alternative. Search which genes are involved in different cancer types would help scientists proceed with new methods for finding a cure for this disease. This article will depict which genes and their location on which chromosomes, specifically on chromosome 11, are related to different types of cancer.

Chromosome 8

Chromosome 8 spans more than 146 million DNA base pairs, and represents between 4.5 and 5 percent of the total DNA in cells. Sixteen percent of these genes and their mutations have been identified to play a role in cancer development. Cancer is a genetic disease at the somatic cell level. Multiple gene mutations usually precede them throughout one’s life. Oncogenes such as Myc, Lyn, Atad2, etc., from chromosome 8 promoted cancer cell proliferation, invasion, and migration. The increased expression of these proteins can transform a normal cell into a cancer cell. Chromosome 8 also houses multiple tumor suppressor genes, such as Dlc1, E2f5, Gata4, Ido1, etc. These proteins, when expressed, reduce the chances of tumor initiation within cells. Thus, mutations leading to the reduced expression of these genes are associated with multiple cancers. Mutation of other functional genes like Ank1, Ctsb, Ext1, Il7, etc., has also been implicated in various cancers for their role in increasing the invasive nature of cancers by regulating angiogenesis and facilitating cancer metastasis. Cancers can also stem from the translocational mutations of genes in chromosome 8. This chapter explains essential cancer genes, genetic mutations, and gene variations that can cause an increased risk of cancer and its progression.

Chromosome 5

Chromosome 5 presents an extensive collection of genes, and includes several cancer-associated ones. The contribution of chromosome 5 in abnormalities is evident through somatic translocations, germline, somatic, and, in some instances, expression of genes. Various syndromes are associated with chromosome 5, such as 5q minus syndrome, leading to the development of acute myeloid leukemia, PDGFRBassociated chronic eosinophilic leukemia contributing to acute myeloid leukemia, and myelodysplastic syndromes. Studies propose that a few genes on chromosome 5 play important roles withinside the increase and department of cells. When chromosome segments are deleted, as in a few instances of AML and MDS, those crucial genes are missing. Without those genes, cells can develop and divide too speedy and in an out-o- -control way. Researchers are trying to perceive the genes on chromosome five that might be associated with AML and MDS.

Biology of Cancer

Loss of genomic stability in the cell due to defects in the checkpoint of DNA damage, mitotic checkpoint, and telomere maintenance led to increased incidences of base pair alterations. Therefore, that genomic instability plays a critical role in tumor initiation and progression. Tumor progression requires a dynamic tumor/normal exchange in their microenvironment to support tumor growth. The histological alteration seen in the tumor at early stages confirms that the surface between the epithelium and the stroma undergoes progressive disturbance. Tumor progression is also affected by the immune system in which chronic inflammations promote the growth of tumor. Tumor cells experience altered metabolic profiling to support their growth. Cancer cells are characterized by uncontrolled cell division. For that, they utilize glucose as a source of energy to help them grow faster than normal cells. Hence, Glycolysis is a key metabolomics pathway consumed at a high rate during carcinogenesis.

Swellings of Orofacial Structures in Children

Orofacial swelling is clinically a common problem found in pediatric dental patients. The causes of these swellings are mostly diverse, and the knowledge about specific clinical as well as imaging manifestations along with the most affected sites of these swelling is needed for the formulation of a differential diagnosis. Mid-facial nonprogressive swelling is usually suggestive of a congenital defect (like a cephalocele, nasal glioma, epidermoid cyst or nasal dermoid). Swelling that is slowly progressive, may be indicative of a neurofibroma, hemangioma, vascular malformation, lymph angioma, pseudocyst or fibrous dysplasia. In cases of facial swellings that are rapidly progressive and associated with cranial nerve deficits, rhabdomyosarcoma, Ewing sarcoma, Langerhans cell histiocytosis, metastatic neuroblastoma and osteogenic sarcoma should also be included in the differential diagnosis.

Subject Index

Heterocyclic Anti-cancer Compounds Derived from Natural Sources with their Mechanism of Action

The variety of natural compounds is indispensable due to their mechanism of action. For many years, natural compounds have been used to develop new classes of chemotherapeutic agents. Chemotherapeutic agents derived and synthesised from natural sources could be the best possible alternatives to minimise the harmful aftereffects of conventionally used agents against cancer, especially oral and maxillofacial carcinoma and tumors. The proposed chapter concentrates on recent research on various classes of natural scaffolds and their analogues that possess potent antitumor activity. Moreover, we would like to provide an analysis of preclinical and/or clinically investigated natural compounds. These compounds and their synthetic heterocyclic analogues were found to be obtained through bioactivity and mechanism of actiondirected isolation and characterization, conjoined with modification using rational drug design-based approaches and analogue synthesis. Structure-activity relationships, structural change, and molecular mechanisms of action will all be examined.

Subject Index

Updates on Pediatric Hepatoblastoma

The developing human liver is embryologically central in embryogenesis. It plays a significant role as a hematopoietic and endocrine organ. During the development, hepatocytes change their phenotype. They vary from blueish cells to cells with an eosinophilic nuance and decreased nucleus to cytoplasm ratio. Apart from congenital abnormalities of this organ and inflammatory conditions that can populate medical charts in childhood and youth, the liver's neoplastic transformation in childhood and adolescence is a rare event. In children younger than three years, the liver's most dramatic neoplasm is represented by the occurrence of hepatoblastoma. It is an embryologic tumor. It retains the suffix “blastoma,” similar to neuroblastoma as any other embryologic tumor. Hepatoblastoma originates presumably from the primitive embryo-fetal progenitors. In this chapter, we update our knowledge of this pediatric tumor, specifically the pathology and the treatment

Monitoring Therapeutic Response in Cancers: A Raman Spectroscopy Approach

Cancer is a multifactorial disease that is often asymptomatic and is thus

detected at an advanced stage. Late detection and resistance to treatment are two of the

major reasons for poor prognosis. The inherent limitations of conventional tools in

evaluating therapeutic responses, raise the need to monitor such responses during

treatment. Raman spectroscopy is a rapid, label-free, minimally invasive optical

vibrational spectroscopy technique that has been widely employed for cancer detection.

There is also significant literature on its applications in intraoperative surgical margin

assessment, chemotherapeutic drug monitoring, and prediction of radiation response.

However, most books and reviews focus on the diagnostic and screening applications

of Raman spectroscopy. This chapter describes the role of Raman spectroscopy in the

therapeutic monitoring of cancers and discusses its prospective applications. The

present work provides a brief introduction to the basic principles of Raman

spectroscopy, concise information on cancer aetiology, pathogenesis, diagnosis and

therapeutics, and applications of Raman spectroscopy in the therapeutic monitoring of

cancers. The role of Raman spectroscopy in monitoring conventional treatment

modalities such as surgery, radiotherapy, and chemotherapy, along with novel

treatment approaches such as immunotherapy and cold atmospheric plasma therapy, is

discussed in detail. The chapter concludes with a brief introduction to the emerging

field of Raman spectroscopy and artificial intelligence.

Chimeric Antigen Receptor (CAR) T Cell for Pediatric Solid Tumors: The Next Frontier in Cancer Treatment

Combiningthe advancements in genetic engineering technologies and the principle knowledge of cancer immunology, chimeric antigen receptor (CAR) T cell therapy has emerged as a promising therapeutic modality for cancers. The function of CARs is to redirect the immune response to attack cancer cells in a specific manner. Up to date, multiple CAR configurations have been designed to ensure safety and to enhance in vivo persistence and therapeutic potency. A number of clinical trials of CAR T therapy for pediatric solid tumors are underway, mainly focusing on neuroblastoma patients. Although CAR T therapy has been approved by the US Food and Drug Administration (FDA) for hematological malignancies, disappointing response rates have been reported in solid cancers due to several hindrances. Proper target antigen selection, inefficient T cell trafficking, and the immunosuppressive nature of the tumor microenvironment (TME) are the main factors limiting CAR T function. In order for CAR T therapy to become successful in this matter, these challenges must be addressed. The future of CAR T therapy is moving toward the development of the “off-the-shelf” universal CAR T product in the hope of providing cancer treatment to a large population. This chapter reviews the principles of CAR design, current clinical trials, limitations, and future prospects of CAR T cells for pediatric solid tumors.

MDM2-p53 Antagonists Under Clinical Evaluation: A Promising Cancer Targeted Therapy for Cancer Patients Harbouring Wild-Type TP53

Mutation of TP53 occurs in about 50% of both sporadic and familial cancer cases. In the remaining malignant tumours harbouring wild-type TP53, it seems that p53 function is suppressed via other mechanisms, including MDM2 upregulation. In addition to frequent loss of p53 function in most types of tumours, the multi-functional transcription activity and tumour suppressor impact of p53 encouraged an enormous effort to introduce novel anti-cancer agents targeting p53. Different synthetic nongenotoxic inhibitors have been advanced to prevent the interaction between p53 and MDM2 and correct p53 dysfunction, of which some are still at early stages of development, and many have recently entered into clinical trials. In spite of the potential merits of targeting p53, including less damage to normal cells, fewer adverse events, and more efficiency, it has its potential drawbacks, which are needed to be addressed. Moreover, activated p53 impacts other biological processes making p53 restoration therapy more complicated. This issue can be resolved through the identification of biomarkers that predict sensitivity to these anti-cancer drugs, combined treatment, and optimization of p53-targeted therapy.

In this chapter, we review the role of TP53 as a tumour suppressor gene, targeting the interaction between p53 and MDM2 as a strategy for the treatment of malignancies and p53-MDM2 antagonists with emphasis on those that have been used in clinical trials. Other aspects of MDM2 inhibitors, including their predictive biomarkers, their side effects, resistance mechanisms, and combined treatment of MDM2 antagonists with other anti-cancer drugs, which potentially improve their clinical efficacy and patient stratification, will also be discussed briefly.

Subject Index

Breast Surgery

At the end of week 4 of human embryonic development, paired thickenings appear in the ectoderm on the ventral aspect of the torso. Extending from the axilla to the inguinal region, they form the mammary ridges or “milk lines.” Subsequently they regress and leave a pair of primary mammary buds at the level of the fourth and fifth inter- costal spaces. The primary buds thicken into lens-shaped mammary placodes. Epithelial cells invade the underlying mesenchyme during weeks 7 and 8 to form the primitive mammary disk. In week 9, a surge of mesenchymal proliferation occurs, coincident with a thinning of the overlying epithelium. A dense mesenchymal stroma then coalesces around the bud. Between weeks 10 and 12, epithelial buds form, begin to branch, and extend into the epithelial–mesenchyme bound- ary. By the first half of the second trimester (weeks 13–20), there are 15–20 solid epithelial cords that converge at the nipples. Ramification processes continue to week 32, when the cords undergo apoptosis to establish tubules and alveoli. At birth, male and female mammary glands are equally formed. There are 20 lactiferous ducts draining into the dimple. In later stages of the final trimester, the mesoderm underlying the dimple changes it into a true nipple with an areola. Placental estrogens during the final weeks of gestation cause breast buds to enlarge to create a true breast nodule at birth, about 1 cm in size, in both genders.

Pediatric Malignancy

Cancer is the second leading cause of death in children after trauma and accounts for approximately 11% of all pediatric deaths in the United States. In the western countries, leukemia, central nervous system (CNS) tumors, lymphomas, neuroblastomas and nephroblastomas account for most pediatric malignancies. Neuroblastoma and nephroblastoma are among the more common solid abdominal tumors. The prognoses for these cancers have improved after numerous multicentre trials. The following description will be restricted to the most commonly encountered tumors in children.

Head and Neck Surgery

Based on the investigation or attribution of the cause in children, lesions of the head and neck can be divided into different categories. Infection, Trauma, neoplasm, or congenital origin are some of the cause of lesions. The hemangioma, Lymphangiomas and cystic hygroma in children, are the widespread benign neoplasm. In children, the malignant neoplasms may include neuroblastoma, lymphoma, and rhabdomyosarcoma. The abnormal growth of cells like primary or metastatic masses in the head and neck, thyroid and parathyroid lesions, or the traumatic injuries of the head and neck represents malignant neoplasm. This chapter discusses the common congenital head and neck malformations as well as inflammatory lesions.

Cannabinoid-based Anti-cancer Strategies: Slowly Approaching the Bedside

Modulation of the endocannabinoid system has emerged as a potential therapeutic strategy for the treatment of diverse types of cancer and related pathologies. Thus far, the use of specific cannabinoids has been primarily approved for the management of chemotherapy-induced side effects. Palliative actions of cannabinoids include the control of nausea and vomiting, pain alleviation and appetite stimulation. Moreover, a growing body of research has exposed the anticarcinogenic potential of cannabinoids. In vitro and in vivo studies have shown that endogenous, plant-derived and synthetic cannabinoids can effectively modulate tumor growth in diverse cancer models. Although this has not yet reached the bedside, ongoing clinical trials and research efforts may approach cannabinoid-based antitumor therapies to cancer patients in the near future.

So far, studies on cannabinoids as antitumor agents have been mainly focused on understanding the mechanism of action of well-known phytocannabinoids such as Δ9-THC or CBD. However, novel cannabinoids with antitumor properties are also emerging in the literature. In this chapter, we aim to provide an updated overview of the therapeutic potential of cannabinoids in cancer. We will comprehensively summarize the diverse cannabinoid structures exerting antitumor properties analyzing the molecular basis of these actions. Recent and ongoing clinical trials will be considered to provide a deeper insight into the current scenario of cannabinoids in oncology.

Pathologies of the Peritoneum, Mesentery and Diaphragm

Pathologies of the peritoneum, mesentery and diaphragm are uncommon, making their diagnosis more challenging. We present the main issues in diagnosis and treatment. Peritonitis represents acute inflammation of the peritoneum that can be caused by perforation, inflammation or gangrene of an intra- or retroperitoneal structure. The most frequently encountered peritoneal tumours are metastases originating in gastrointestinal, ovarian, lung, pancreatic and breast adenocarcinomas. Lymphomas can primarily or secondary affect the peritoneum. There are two main categories of diseases affecting the mesentery: diseases that start from the mesentery (which can also affect neighbouring organs) and diseases that originate in neighbouring organs. The most encountered hernias of the diaphragm are those occurring through the oesophageal hiatus, but there can also be congenital hernias (oesophageal, Morgagni and Bochdalek) or through post-traumatic defects. As in all other organs, primary diaphragmatic tumours can be classified as benign (cyst and lipomas) or malignant (rhabdomyosarcoma and fibrosarcoma), with other types of primary tumours than those aforementioned being very rarely seen.

Cytotoxicity Through Molecular Targets Involved in Apoptosis. Where Should We Further Search for Mushrooms Functionalities in Future Cancer Treatment?

Apoptosis is considered as a classical way of programmed cell death and important control mechanism of cell homeostasis. Cancer cells acquire different instruments to circumvent programmed cell death. This promotes uncontrolled growth and frequently confers chemoresistance to tumor cells. Activation of apoptotic signaling pathway has been a target of anti-cancer drugs in an induction of cytotoxicity. The mechanism of apoptosis is complex and includes many pathways. This chapter will focus on the current knowledge of apoptosis-triggering approaches in cancer therapy, as well as on mushroom extracts and isolated compounds acting as initiators of apoptosis through regulation of genes expression involved in cancer cell death. Furthermore, we pointed out directions for novel search for mushroom functionalities in this experimental field and discuss the possible further steps for exploration on the in vitro and in vivo levels.

Oesophageal Neoplasms

Oesophageal cancer is the eighth most common cancer and the sixth most common cause of death from cancer. Histologically, oesophageal cancers are composed mainly of two variants: squamous cell cancer and adenocarcinoma of the oesophagus. Benign tumours are rare. The aetiology of squamous cell cancer is largely unknown but adenocarcinoma progresses from Barrett’s oesophagus. Diagnosis is by endoscopy and staging is done by a combination of CT, EUS and PET/CT. Many tumour markers have been elucidated and their potential importance in diagnosis and treatment is actively pursued. Endoscopic therapy is appropriate for node negative patients with early cancers limited to the mucosa. Less than 30% of all patients with oesophageal cancer are suitable for curative treatment. Surgical treatment by oesophagectomy is appropriate for medically fit patients with T<4, N<3 and M<1 tumours. Neoadjuvant therapy (chemoradiotherapy or chemotherapy) is advocated for all tumour types. The management of patients with locally advanced or metastatic oesophageal cancer and patients with poor general medical condition must be individualised based on stage, characteristics of the tumour, patient’s medical condition and patient preference. The aim of palliative treatment is to achieve rapid and sustained relief of dysphagia. Chemotherapy alone or in combination with radiotherapy should be considered with other palliative measures. Canalisation of the tumour and restoration of swallowing is best achieved using self-expanding metallic stents. Best supportive care may be appropriate in frail patients with advanced disease at presentation.

Subject Index

Pediatric Hematological Malignancies – Clinical Manifestation, Treatment and Follow-Up

Hematological malignancies are the forms of cancer that begin in the cells of the blood- forming tissue, such as the bone marrow. Childhood blood cancers are relatively rare but are still found to be the major cause of death in children aged 1-14. Early detection increases the chances of successful treatment which paves the way to reduce the rate of mortality. Leukemias and lymphomas account for more than one half of new cancer cases in children. Despite major advances – from an overall survival rate of 10 percent to nearly 90 percent today, for many rare cancers, the survival rate is much lower. Enhancement of anti-leukemic efficacy and reduction of treatment related morbidity or mortality can be achieved by targeted therapy, but requires detailed understanding of pathways and genetic defects involved in leukemogenesis.

Spatial Geostatistical Analysis Applied To The Barroso-Alvao Rare-Elements Pegmatite Field (Northern Portugal)

The geological science has been in recent years an excellent playground for GIS applied studies, especially regarding the mineral deposits prospectivity. Other fields of study in the geological science (e.g. soil risk management, mining exploitation, geothermal resources…) also took advantages of this geocomputing methodology to extract spatial information. The geoscientist community fairly agrees that interrelations between mineral deposits and certain geological features are observed in the terrain, presenting also a non-random spatial regional distribution pattern in a vast majority of cases. This is where the spatial analysis using geocomputational techniques, in this particular case for rare-elements pegmatites, can be used as a great analytical tool to produce a mapping of mineral potential, or unveil the regional zonation patterns for this type of mineralization. In this study, statistical spatial analyses were performed for the pegmatites to highlight any possible relationship, or lack of it, between them and the surrounding granitic plutons, shear zones or schistose foliations. To accomplish our proposed objectives, the geocomputational method of Distance to Nearest Neighbours (DNN), Ripley’s L’- function and pegmatites orientations families were employed to study the spatial distribution pattern of the pegmatites, whereas Euclidean distance and Kernel density distributions aimed the spatial association between these same pegmatites to the various geological features within the study area. The obtained results show: i) Pegmatites spatial distribution following a clustering pattern, presenting the Lienriched pegmatites a higher rate and extent compared to the total pegmatites, as well as a spatial association with moderate to high pegmatites density; ii) Three distinct families of pegmatites orientation; iii) No statistically significant spatial relationship for the total pegmatites or Li-enriched relatively to the granitic pluton; iv) A regime of deformation within the study area, suggesting the presence of corridors of deformation with NW to NNW orientations; and v) Pegmatites spatial emplacement suggesting shear-zones control.

Anatomy of Intraoral Techniques

Anatomy (from the ancient Greek anatom

Integral-Balance Solution to Nonlinear Subdiffusion Equation

Improved double-integration technique to approximate integral-balance solutions of non-linear fractional subdiffusion equations has been conceived. The time-fraction subdiffusion equation with Dirichlet boundary condition and a powerlaw fractional diffusivity has been chosen as a test example. Problems pertinent to approximation of time-fractional Riemann-Liouville derivative when the distribution is expressed as a parabolic profile with unspecified exponent and accuracy of the solutions have been analyzed. The final solution is a closed-form can be presented with either a similarity variable of a fractional order as independent variable or by an effective similarity variable incorporating the effects of both the fractional order and the nonlinearity of the diffusion coefficient. Optimization problem pertinent to determination of the optimal exponent of the parabolic profile, dependent on both the fractional order and the nonlinearity parameter of the diffusion coefficient, has been developed by a modified technique transforming the time-varying domain of integration into one with fixed boundaries. It was clearly defined that the approximate profile can exhibit a concave behaviour, typical for subdiffusion relaxation processes when the non-linearity of the diffusion coefficient is low and the fractional order is high. Otherwise, the increase in the nonlinearity of the diffusion coefficient results in convex profiles typical for the degenerate diffusion behaviour.

The Contrivance of General Theory of Relativity: Unification of Abraham, Einstein and Nordström’s Hybrid Theoretical Models

The aim of the chapter is to amend the received view on the general theory of relativity (GTR) genesis and advancement by taking into account common scientific practice of its functioning, the history of science data and certain philosophy of science arguments. The inter-theoretical aspect of the GTR genesis as an instance of perspicuous epistemological model of mature theory change that hinges upon ‘old’ theories encounter and interaction is scrutinized. I strengthen arguments in favour of the tenet that the dynamic creation of GTR had been continually governed by internal tensions between two research traditions, that of special relativity and Newton’s gravity. The encounter of the traditions, their interpenetration and intertwinement engendered the rival programmes of relativistic theory of gravity construction: the programmes of Abraham and Nordstrӧm – on the one hand – and Einstein’s programme – on the other. The encounter created the hybrid realm at first with an irregular set of theoretical models. The rival approaches of Einstein, Abraham and Nordström grew closer and eventually were transformed by Einstein into complementary ‘mathematical’ and ‘physical’ strategies of a general synthetic research programme that put forward the Entwurf and the GTR. Step by step, on eliminating the contradictions between the models contrived, the hybrid set was put into order by Einstein via the principle of equivalence. As in the STR case, Einstein was able to freely juxtapose Nordstrӧm, Abraham’s and his own non-metric theoretical schemes without reducing one to the others. It is contended that the main reason for the GTR ‘victory’ over the rival programmes of Abraham and Nordström was a synthetic character of Einstein’s programme. Einstein’s programme did supersede the rival ones because it did ingeniously assimilate some ideas of the Nordström programme as well as some presuppositions of the programme of Abraham. Einstein had put forward as a basic synthetic principle the principle of equivalence that radically differed from that of rival approaches by its open, flexible and regulative character. As a result of reconciling and amalgamating the ‘physical’ and ‘mathematical’ approaches, embodied in Abraham, Einstein and Nordström’s crossbred theoretical models , Einstein was able to explain the anomalous motion of Mercury.

Clinical Trials of Curcumin, Camptothecin, Astaxanthin and Biochanin

Use of natural products as therapeutics, has been in practice even before the advent of modern medicine. Traditional medicinal systems like Ayurveda, Siddha and Unani which prescribe medicines based on natural products have been in practice for centuries, authenticating the medicinal efficacy of these drugs. However, with the advent of modern medicine, the focus shifted from medicines based on formulations to mostly single component drugs. Also, norms were established to standardize methodologies for clinical trials that will establish safety and efficacy of the drugs before human use. These stringent norms meant that most of the traditional medicines could not be used in the current medicinal system of treatment as drugs. Nevertheless, researchers have repeatedly mined these traditional natural sources and other similar materials for compounds with potential therapeutic value. Such research has yielded compounds like acetylsalicylic acid (aspirin), morphine, quinine and even Nobel prize winning natural products like artemisinin (anti-malarial agent) and avermectin (antibiotic). In fact, more than half of the drugs approved by FDA have either direct or indirect inspiration from natural products. Apart from these, several interesting natural products are also under various stages of clinical trials varying from inflammation, infection to dietary supplements. The present chapter reviews some of these attractive natural products namely curcumin, camptothecin, astaxanthin, and biochanin that are currently under various stages of clinical trials for their application as therapeutics in various diseases. The chapter also deals with challenges such as lead optimization, formulations and delivery systems that should be addressed by researchers to move the natural product from the realm of nutraceuticals to the area of clinical medicine.

Microtubules as Anti-Cancer Drug Targets

In developmental biology, all cellular events are suitably synchronized to ensure proper growth and development of any multicellular organism. A healthy adult tissue is often characterized by stem cells that can undergo orchestrated cell division and differentiation. Disruption of these events often leads to cancer resulting from the accretion or accumulation of the genetic and epigenetic changes that occur at the somatic as well as the germ line levels. In the recent years, significant progress has been made in the early detection, treatment and prevention of cancer. Targeted cancer therapies include the use of apoptosis inducing drugs and drugs that target microtubules among others. Over the past few years, drugs that inhibit microtubule dynamics have been successfully used as anticancer drugs. They can either be microtubule stabilizers (Vincristine, Vinblastine, Colchicine etc.) or microtubule destabilizers (Paclitaxel, Docetaxel, Epithilones, Taccalonolides etc.). Recently, new classes of compounds have been identified that interfere with cell growth and proliferation as a consequence of binding to tubulin αβ- dimers. Natural compounds like Curcumin have shown to inhibit tubulin activity. Whereas some antimitotic agents like Aurora A/B, Pentoxifylline, benzimidazole derivatives, combrestatin, polymeric nanoparticles etc. have been reported to show significant effect in the treating several types of cancer which were previously deemed untreatable. The following chapter acknowledges the presence of these anti-tumor compounds and how they target microtubules and further aid in the treatment of various cancers afflicting human beings.

Infra-sellar and Nasopharyngeal Craniopharyngioma

The infra-sellar and nasopharyngeal craniopharyngiomas (CPs) were the special type, which predominantly presented in the children. In this chapter, we briefly depicted the clinical features of this type of tumor. Patients suffered with this type of CP were rarely more than 16 years old. The pathology was all adamantous tumor. As concerned to the clinical manifestation, except the pituitarism, growth retardation, and optical pathway injury, the pediatric patients always suffered with rhinocleisis, homorrhinia and airway obstruction. As extensive involvement, it was quite difficult to radical remove the tumor. As the result, tumor recurrent caused poor quality of life. Until now, the best treatment strategy was still missing.

Cancer and its Treatment: Development of Anticancer Chemotherapeutic Agents from Natural Products

Over the last 5 decades, biologically active compounds derived from natural resources have provided a number of useful cancer chemotherapeutic drugs. The search for natural product based drug candidates is growing rapidly with the advancements in drug discovery and development techniques in recent years, with the active fractions and isolates of marine organisms along with terrestrial plants. Microorganisms are also being explored for their anti-cancer activities. The present review highlights the information about occurrence, types, clinical features pathophysiology and etiology of cancer as well as conventional and recent advancements in anticancer drug development along with description of selected medicinal plants and compounds derived from natural sources or their derivatives with potential use as cancer chemotherapeutic agents. It is expected that such promising leads from natural origin tend to create extensive interest among researchers including medicinal chemists and pharmacologists working in anticancer drug research and therefore the availability of a given brief information about cancer and anticancer drug development focused on natural product may be proved useful to develop preliminary ideas of biochemical pathways and key enzymes regulating these pathways as well as new targets involved in different stages of the disease along with chemotherapeutic agents which selectively target a specific signaling pathway through structure-activity relationships and preclinical trials.

Natural Products as a Unique Source of Anti- Cancer Agents

Cancer is a major public health problem and the second leading cause of premature deaths worldwide, accounting for an incident rate of 2.6 million cases per year, mainly in Europe and the United States. This book chapter describes the historical aspect of cancer, its treatment modalities and history of natural compounds being used as anti-cancer agents. Role of marine natural compounds and their derivatives in cancer prevention, like, alkaloids, amine derivatives, macrolides, peptides and polypeptides are described in this chapter. Both, role of natural compounds extracted from plants and microbial sources are discussed along with their molecular targets and interactions to kill the cancer cells. Most of the medicinal compounds derived naturally are synthesized semi-synthetically for commercial purposes. They are then formulated into proper dosage increasing their costs. But for many natural compounds clinical trials are still to be carried out to validate their use in cancer therapy.

Immune System in Cancer

Our immune system is a dynamic environment that is orchestrated by a network of immune cells and signalling molecules and is differentially expressed and regulated at different stages of life. Interestingly, components of the immune system function differently under diseased or non-diseased state, healthy or immune-deficient state. Cancer is generally regarded as a genetic disease and caused from inflammation. Due to the complex nature of the disease, it is necessary to understand how the immune system responses in a tumor environment. A detailed understanding on the cancer immuno-biology will enable formulation of appropriate treatment strategies for cancer.

Tumor Resistance Mechanisms to Inhibitors Targeting the Epidermal Growth Factor Receptor– Part I: Extracellular Molecules

Since its discovery several decades ago, the Epidermal Growth Factor Receptor (EGFR) has become one of the most extensively studies receptor tyrosine kinases. However, despite continued insight into the cancer promoting properties of the EGFR and its downstream signalling substrates, clinical use of agents targeting the EGFR continue to yield modest outcomes. Clinically, approved anti-EGFR therapeutics can successfully inhibit receptor activation. However major tumour regression is observed in only 10-30% of advanced unselected cancer patients, with most patients showing no therapeutic benefit. Furthermore, those who initially respond commonly relapse presenting with reoccurrence of tumours that are frequently resistant to the original therapy. In addition, the standard course of treatment of such agents is estimated to cost between “US $15,000-80,000/patient” for an improved overall survival of only 1-2 months. Therefore, it is both medically and financially critical to determine the true molecular mechanisms of tumour resistance, and how it can be overcome. In these 2 back-to-back chapters, we will provide an overview of the progress made in targeting the EGFR and discuss the challenges presented by the numerous molecular mechanisms currently identified, leading to overall refractory outcomes to anti-EGFR therapeutics. In this chapter (Part I) we will specifically focus on the resistance mechanisms driven by alterations in ligand and receptors of the EGFR family and cross-talk between EGFR receptors and non-EGFR family members.

Other Malignant Primary Tumors of the Liver

• The most common malignant hepatic tumor is by far hepatocellular carcinoma, followed by intrahepatic cholangiocarcinoma. However, other primary malignancies can occur and require specific approaches.

• Cystadenocarcinoma is a cystic tumor that usually develops from hepatic biliary cystadenoma. In both cases, radical surgical resection is the treatment of choice.

• Primary hepatic lymphomas are very rare (contrary to the frequent secondary involvement of the liver in disseminated non-Hodgkin lymphoma) and frequently associated with hepatitis C virus infection. Chemotherapy is efficient for most tumors and surgical resection indicated for complete resection of limited tumors or to reduce tumor burden before systemic therapy.

• Most cases of hepatoblastoma occur in childhood. Prognosis in adults is much poorer due to late diagnosis. Treatment is based on complete surgical resection.

• Hepatic epithelioid hemangioendothelioma is a rare vascular tumor with variable degrees of aggressiveness. Surgical resection (including liver transplantation) is the best approach when no extrahepatic involvement is present.

• Angiosarcoma, the most common primary hepatic sarcoma, represents up to 2%of primary liver malignancies, occurs more frequently in aged patients, and carries a very poor prognosis. Surgical resection is the best option in resectable cases, although recurrence is very common. Chemotherapy and trans-arterial therapy are used alone (to prevent bleeding and avoid tumor growth) or in combination with surgery.

Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis

Tumor cell migration and invasion play fundamental roles in cancer metastasis. The mammalian target of rapamycin (mTOR), a highly conserved and ubiquitously expressed serine/threonine (Ser/Thr) kinase, is a central regulator of cell growth, proliferation, differentiation and survival. Recent studies have demonstrated that mTOR also plays a critical role in the regulation of tumor cell motility, invasion and cancer metastasis. Current knowledge indicates that mTOR functions as two distinct multiprotein complexes, mTORC1 and mTORC2. mTORC1 phosphorylates p70 S6 kinase (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), and regulates cell growth, proliferation, survival and motility. mTORC2 phosphorylates Akt, protein kinase C α (PKCα) and the focal adhesion proteins, and controls the activities of the small GTPases (RhoA, Cdc42 and Rac1), and regulates cell survival and the actin cytoskeleton. Here we briefly review current knowledge of mTOR complexes and the role of mTOR signaling in tumor cell migration and invasion. We also discuss recent findings about the mechanism by which rapamycin inhibits cell migration, invasion and cancer metastasis.

Calixarenes in Biotechnology and Bio-Medical Research

Application of calixarene derivatives in biotechnology and bio-medical researches is reviewed in this article. Results on antiviral, bactericidal, antithrombothic, antituberculosis, anticancer activities of modified calixarenes are presented. Transfection ability, specific protein complexation, enzyme mimic, membranotropic properties and toxicity of modified calixarenes are described.

Targeted Cancer Therapy: The Roles Played by Antibody-Drug and Antibody-Toxin Conjugates

In recent years, antibody therapeutics have been widely and successfully used in treating cancer. Antibodies that specifically bind tumor surface antigens can also be used as therapeutics, and over 35 of them are in clinical use (e.g. trastuzumab, bevacizumab and cetuximab). However, some unmodified antibodies against tumorspecific antigens lack therapeutic activity. Conjugation to cytotoxic agents can increase the antibodies’ activity and, at the same time, enable extremely cytotoxic drugs to be used.

Antibody-delivered drugs and toxins are poised to become important classes of cancer therapeutics. These biopharmaceuticals have potential in this field, as they can selectively direct highly potent cytotoxic agents to cancer cells that present tumorassociated surface markers, thereby minimizing systemic toxicity. The activity of some conjugates is of particular interest receiving increasing attention, thanks to very promising clinical trial results in hematologic cancers. Over forty antibody-drug conjugates and six immunotoxins now in clinical trials, as well as some recently approved drugs, support the maturity of this approach.

This chapter focuses on recent advances in the development of these two classes of biopharmaceuticals: conventional toxins and anticancer drugs are described, together with their mechanisms of action. The processes of conjugation and purification, as reported in the literature and in several patents, are discussed and the most relevant results in clinical trials are listed. Innovative technologies and preliminary results on novel drugs and toxins, as reported in the literature and in recently-published patents (up to January 2015) are lastly examined.

Mechanisms of Biological Actions of Inositol and InsP₆ I: Cell Survival, Proliferation and Differentiation

A fundamental defect in cancer cells is the abnormal and uncontrolled cell proliferation. Along with that, there is de-differentiation to an immature or primitive phenotype. InsP₆ and inositol normalize the abnormal cell proliferation rate and induce increased differentiation so that the cancer cells begin to look and behave akin to normal cells. Examples of these are shown in colon cancer, erythroleukemia and mammary cancer, and rhabdomyosarcoma cells. In colon cancer cells that produce the cancer marker ß-D-Galactose-[1→3]-N-acetyl-D-galactosamine (Gal-GalNAc), InsP₆ inhibits the expression of the marker in the intracellular mucus without suppressing the production of mucus, a normal function of colon epithelial cells.

Experimental Cancer Regression by InsP₆ & Inositol

Towards the eventual goal of translating the cancer inhibitory effect of inositol & InsP₆ seen in experimental animals in vivo to cancer prevention and therapy in humans, studies of human cancer cells lines were performed in vitro; and human cancer cells xenotransplanted in nude mice were used to test the therapeutic potential. A consistent and reproducible broad-spectrum anticancer action of InsP₆ ± inositol was observed in various models; in human breast cancer model InsP₆ showed synergism with standard chemotherapeutic agents Adriamycin or Tamoxifen. Suppression of cancer growth was seen in xenotransplanted rhabdomyosarcoma model and regression of preexisting cancer was seen in hepatoma model. InsP₆ ± inositol also inhibited various steps in cancer metastasis, inositol potentiated the action. These findings are compelling reasons for application of InsP₆+inositol for human cancer control.

Current and Future Medical Therapy, and the Molecular Features of Adrenocortical Cancer

Adrenocortical carcinoma (ACC) is a rare neoplasm with very poor prognosis despite the recent development of aggressive antitumor therapies. The cause of adrenal cancer remains elusive, but some molecular mechanisms could be responsible for its development. Target-specific therapies have been developed for a number of human malignancies and have resulted in therapeutic benefits in some cancer patients. However, these therapies are only effective in cases in which the corresponding targets are expressed in tumor tissues. Molecular analysis has had a significant impact on the understanding of the pathogenetic mechanism of ACC development and the evaluation of prognostic and predictive markers, among which alterations of the IGF system, the Wnt pathway, p53 and molecules involved in cancer cell invasion properties and angiogenesis seem to be very promising. These molecular markers may not just play a role in the biology of these tumors and have prognostic implications, but can also be used as potential targets for treatment. The aim of this chapter is to summarize the genetic and molecular events implied in the pathogenesis of ACC and to highlight challenges to the development of anticancer agents in recent patents.

Understanding Tumor Metabolism and its Potential as a Target for the Treatment of Cancer

The role played by oncogenes and tumor suppressors in the genesis of cancer is well established. Considering that cancer cells are a product of genetic disorders that alter crucial intracellular signaling pathways associated with the regulation of survival, proliferation, differentiation and death mechanisms it is not surprising that traditional antitumor approaches target specific molecular players whose action/expression is altered in cancer cells. However, because the physiology of normal cells is controlled by the same signaling pathways that are disturbed in cancer cells many cancer therapies also cause important side effects and multidrug resistance, the main causes of therapy failure. Since the pioneering work of Otto Warburg, over 80 years ago, the subversion of normal cellular metabolism by cancer cells has been highlighted by many studies. In recent years, the study of tumor metabolism has received considerable attention because metabolic transformation is now recognized as a crucial cancer hallmark and a direct consequence of disturbances in oncogenes and tumor suppressors. Far from being a completely understood phenomenon, metabolic transformation constitutes a challenge for researchers and a potential target for cancer therapies. In this chapter, we describe the anabolic and catabolic pathways of cancer cell metabolism, compare their functions and regulation with those of non-tumor cell metabolism and discuss some of the major questions in this field of investigation. We also discuss tumor metabolism and metabolic transformations from the perspective of oncogenes, tumor suppressors, miRNAs and protein signaling pathways. Finally, recent attempts to target metabolism as a treatment for cancer are discussed.

Combination Chemotherapy: The Road to Cure

The principles of combination chemotherapy to overcome drug resistance and the use of high intermittent dosage to achieve maximal therapeutic benefits, first learned from studies in childhood acute lymphocytic leukemia, were applied to other hematologic malignancies and to solid tumors. As new drugs that were active against specific malignancies became available, they were tested in combination with other agents. Drugs with different mechanisms of action and no overlapping toxicity were preferentially selected for combination chemotherapy. Cures were achieved in Hodgkin’s disease, testicular cancer and Burkitt’s lymphoma, as well as improved survival in non-Hodgkin’s lymphomas. These major successes occurred in tumors characterized by a relatively rapid proliferating growth rates and were not paralleled by similar results in cancers with slower growth rates.

Targeting Key Signaling Pathways in Pediatric Brain Tumors

Tumors of the Central Nervous System (CNS) are the most common solid tumors in children, and represent a heterogeneous group of diseases. Progress has been made in understanding the biology of some histologic tumor subtypes and a number of involved cell signaling pathways have been identified. As a consequence, molecularly targeted therapies are being evaluated as part of the therapeutic armamentarium against these diseases. Targeting key signaling pathways in pediatric brain tumors is an attractive idea since aberrant signaling pathways may be specific to tumor cells. Pediatric tumors are different from their adult counterparts and offer unique challenges. In addition to the unique pharmacokinetic properties of the CNS (blood-brain barrier and blood-tumor barrier), treatment of children with brain tumors is aimed at the developing brain, which may be more susceptible to effects of therapy, and the effects of signal inhibitors on the post-natal developing brain are largely unknown. Despite these obstacles, inhibitors of signaling networks involving sonic hedgehog, epidermal growth factor receptor, plateletderived growth factor receptor, BRAF, Notch, and others are under clinical investigation and have the potential to bring exciting management alternatives for pediatric CNS tumors in the near future. This article reviews pediatric brain tumors with signaling pathways implicated in their tumorigenesis and current efforts to target them.

Histopathologic Features of the Lung Cancer

Lung cancer is one of the leading cause of cancer death in the world today. The predominant cause of the lung cancer is tobacco smoking. The other main causative agents are asbestos, silica, radon and heavy metals. Histologically carcinomas comprise nearly 99% of lung cancers. Lung carcinomas have two major groups in the classification of the World Health Organization [WHO]. There is a new multidisciplinary classification of lung adenocarcinomas published by the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society. With the improvements in the knowledge of the lung cancer biology, there may be more changes in the histological classification and the treatment.

Myocardial Ischemia, Myocardial Infarction

In this chapter, we address the basic notions of myocardial ischemia and myocardial infarction. Cardiac ischemia changes the electrical activity and the genesis of the action potential and of the resting potential. It can be divided into 3 forms; ischemia, lesion and necrosis. Modification of the QRS complex, the ST segment and T wave is observed. Ischemia is a biochemically reversible anomaly. Moreover, it is mainly ionic, notably potassium disturbances which underlie ST and T wave changes. Lesion is a more severe form of cardiac ischemia but is still reversible, with interstitial oedema and biochemical disturbances. Essentially, it is the ST segment, which is modified, in that it becomes displaced from the isoelectric baseline. The ST segment vector is determined in the same manner as that of the QRS complex: it allows for better localization of the site of the stenosis or obstruction of the culprit artey. The more leads exhibit ST changes, the bigger the territory at risk. A sum total of ST depression or elevation greater than 12 mm in the different leads implies widespread ischemia. The most severe stage of cardiac ischemia is necrosis since there is cellular death with cessation of electrical activity. Neither the action potential nor the resting membrane potential exists anymore and the conduction capability has ceased. The start of depolarisation (QRS) is modified with the apparition of an \"electrical hole\" (Q waves), which could progress as far as the total disappearance of the positive forces (R waves) and a QS morphology; the necrosis is transmural affecting therefore the full thickness of the myocardium. Acute coronary syndrome includes STEMI and non-STEMI. STEMI (ST Segment Elevation Myocardial Infarction) is the acute coronary syndrome with ST segment elevation and non-STEMI is associated with other ST segment changes (negative T waves or ST segment depression) but not ST segment elevation. Electrocardiographically, the electrical changes recorded in the different territories differ according to the coronary artery involved. There is a good correlation between the ischemic zone and the coronary artery affected. Ischemia is recorded by the electrode \"exploring\" the territory implicated. Involvement of the right coronary artery gives rise to inferior wall ischemia and this is characterized on the ECG as changes in leads II, III and aVF. Involvement of the left coronary artery gives rise to anterior wall ischemia and this is characterized on the ECG as changes in precordial leads.

Selective Cyclooxygenase-2 Inhibitors for Malignant Glioma Therapy: Molecular Targets Beyond COX-2

Cyclooxygenase-2 (COX-2) oftentimes is highly expressed in cancer tissues, where it supports tumor development and angiogenesis. Over the past 15 years, newly developed non-steroidal anti-inflammatory drugs (NSAIDs) that are able to highly selectively inhibit this enzyme were hoped to become therapeutic tools for cancer prevention and therapy. However, while chemopreventive effects of certain selective COX-2 inhibitors indeed have been documented, their efficacy for therapy of already established cancers has been unimpressive so far. Intriguingly, the investigation of compounds such valdecoxib, rofecoxib, and in particular celecoxib, has revealed molecular targets besides COX-2, and it appears that some of these non-COX-2 targets may be critically involved in mediating the pro-apoptotic effects of these compounds without any apparent involvement of COX-2. In fact, investigations of a series of close structural analogs of celecoxib demonstrated that it is possible to separate COX-2 inhibitory function from apoptosis-stimulatory function within the molecule. For example, 2,5-dimethyl-celecoxib (DMC) has lost COX-2 inhibitory function, yet still exerts profound cytotoxic potency.

This review will summarize pertinent results from the exploratory therapeutic use of NSAIDs, in particular celecoxib, in preclinical and clinical studies of malignant glioma. Several COX-2 independent targets will be presented, and it will be discussed how DMC has helped to delineate their relevance for the surmised COX-2 independent tumoricidal effects of celecoxib.Angiogenesis, azetazolamide, carbonic anhydrase, celecoxib, diclofenac, 2,5-dimethyl-celecoxib (DMC), endoplasmic reticulum stress, etoricoxib, glucose-regulated protein 78 (GRP78), meloxicam, nimesulide, 3- phosphoinositide-dependent protein kinase-1 (PDK1), rofecoxib, temozolomide, valdecoxib.

Advances in mTOR inhibitors

Mammalian target of rapamycin (mTOR) is the hub of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway, which is one of the most commonly mutated pathways in cancer. mTOR is considered a member of the PI3K-kinase-related kinase (PIKK) superfamily since its C-terminus shares strong homology to the catalytic domain of PI3K. Currently it is known that mTOR functions as two complexes, mTOR complex 1 (mTORC1) and mTORC2. Clinically used rapamycin and rapalogs are allosteric inhibitors of mTORC1 and effective as anticancer agents in various preclinical models. In clinical trials, rapalogs have demonstrated efficacy against certain types of cancer. Recently, a new generation of mTOR inhibitors, which compete with ATP in the catalytic site of mTOR and inhibit both mTORC1 and mTORC2 with a high degree of selectivity, have been developed. Besides, some natural products, such as epigallocatechin gallate (EGCG), caffeine, curcumin, resveratrol and cryptotanshinone, have been found to inhibit mTOR as well. Here, we review the current findings regarding mTOR signaling pathway and discuss the advances in mTOR inhibitors as anticancer agents.

Approach to Pediatric Neck Masses

Pediatric neck masses can be divided into two broad categories: congenital and acquired. The most common congenital neck masses in children are branchial cleft cysts and thyroglossal duct cysts. The majority of pediatric neck masses are acquired and can be sub-classified as either infectious or inflammatory. Commonly encountered benign tumors include hemangiomas and lipomas. Unlike adult neck masses, malignant neoplasms are rare, accounting for only 15% of persistent neck masses. Cervical malignancies in children include rhabdomyosarcoma, lymphoma, and neuroblastoma. A careful history and physical examination is paramount in the diagnostic approach to the pediatric patient with a neck mass. Radiologic and laboratory tests can assist in the diagnosis, and occasionally surgical biopsy is necessary.

Gene Clusters, Molecular Evolution and Disease: A Speculation

Traditionally eukaryotic genes are considered independently expressed under the control of their promoters and cis-regulatory domains. However, recent studies in worms, flies, mice and humans have shown that genes co-habiting a chromatin domain or “genomic neighborhood” are frequently co-expressed. Often these co-expressed genes neither constitute part of an operon nor function within the same biological pathway. The mechanisms underlying the partitioning of the genome into transcriptional genomic neighborhoods are poorly defined. However, cross-species analyses find that the linkage among the co-expressed genes of these clusters is significantly conserved and that the expression patterns of genes within clusters have co-evolved with the clusters. Such selection could be mediated by chromatin interactions with the nuclear matrix and long-range remodeling of chromatin structure. In the context of human disease, we propose that dysregulation of gene expression across genomic neighborhoods will cause highly pleiotropic diseases. Candidate genomic neighborhood diseases include the nuclear laminopathies, chromosomal translocations and genomic instability disorders, imprinting disorders of errant insulator function, syndromes from impaired cohesin complex assembly, as well as diseases of global covalent histone modifications and DNA methylation. The alteration of transcriptional genomic neighborhoods provides a model for studying epigenetic alterations as quantitative traits in complex common human diseases.

Insulin-Like Growth Factor Receptor Inhibitors: Categorical Lack of Efficacy or Lack of Personalised Medicine?

The insulin-like growth factor 1 receptor (IGF-1R) and its associated signalling system provoked considerable interest over recent years as a therapeutic target in cancer. Whilst preclinical evidence for the efficacy of IGF-1R pathway inhibitors is strong, only very modest signals of activity have been observed in the clinical setting thus far. This has prompted several pharmaceutical companies to terminate their respective drug development programmes. Far from representing an ineffective strategy, we believe that the lack of efficacy hitherto observed in unselected trials is at least partially due to a failure to restrict the use of these inhibitors to those most likely to benefit. Both patient and tumor factors, including the complex signalling networks that interact with the IGF-1R pathway, are important mediators of response. In this updated chapter, we focus on the preclinical studies and retrospective clinical data that have attempted to identify biomarkers that predict for efficacy and resistance. Some intriguing results are beginning to emerge which should, in time, prompt for a reappraisal of promising agents and lead to a second generation of clinical trials, this time in populations enriched for those likely to benefit. In particular, we discuss the available clinical data for the IGF-1R antibodies figitumumab (CP-751,871), cixutumumab (IMCA12), ganitumab (AMG-479), dalotuzumab (MK-0646), robatumumab (R1507), the IGF-1R tyrosine kinase inhibitors linsitinib (OSI-906), XL228 and AXL1717, and also consider some more recently developed agents, including the IGF-1/IGF-2 neutralising antibody MEDI-573. Finally, we review some recent patents in the field, including IGF- 1R combination therapeutics and biomarkers.

Microbiology, Virology and Histopathological Sampling and Diagnosis

Ocular samples include: ocular cells or tissue (conjunctiva, cornea, retina, or orbital tissue), bio-fluids such as tears, aqueous or vitreous, therapeutic or cosmetic contact lenses, implanted devices (intraocular lenses, corneal rings), or transplanted tissue (e.g. Infected corneal graft tissue). Sampling extends beyond the careful collection of ocular material to involve sample storage and transfer. Reliable results require avoiding sample contamination at any stage of sampling, storage, and processing. In order to aid the laboratory scientist to provide an accurate interpretation of the investigations, it is extremely important to give details of all relevant clinical history, other related medical conditions, clinical differential diagnosis, and in some cases demographical details such as race, birth place and current postcode. This chapter will provide a précis of common sample collection in ophthalmology and an overview of culture-dependent and independent techniques including immunohistochemistry and molecular biological techniques used for ophthalmological diagnosis.

miRNAs in Myocardial Infarction

The aim of this chapter is to provide an overview on the role of miRNAs in myocardial ischemia, ischemia/reperfusion injury and ischemic preconditioning. Myocardial ischemia due to occlusion of coronary arteries constitutes the major cause of mortality and morbidity of humans worldwide by causing an array of injuries. Timely myocardial reperfusion remains the most effective treatment strategy for reducing myocardial infarct size, preventing left ventricular remodelling, preserving left ventricular systolic function and improving clinical outcomes. However, the full benefits of myocardial reperfusion are not realized, given that the actual process of reperfusing ischemic myocardium can independently induce myocardial injury. On the other hand, heart has endogenous cardioprotective capability against myocardial/reperfusion injury, called ischemic preconditioning. Recent studies indicate that miRNAs are implicated in all these different aspects of myocardial ischemia. This chapter describes the role of miR-1 and mR-133 in myocardial ischemia, miR-21, miR-29 and miR-320 in ischemia/reperfusion injury, and miR-21 and miR-199a in preconditioning.

Stretch Yourself: Some Consent Scenarios

Some Consent Scenarios

It is useful to discuss scenarios that are real or construed to test one's understanding and so 30 scenarios are given for enlightenment based upon the text of founding principles.

Bevacizumab for Malignant Gliomas: Comparative Study with Other Malignancies

Although, the use of temozolomide, as described by Stupp et al. has been hailed as one of the landmark breakthroughs for malignant gliomas, this diagnosis still portends one of the worst prognosis in oncology. Bevacizumab (Avastin) was reported to have favorable results and an acceptable toxicity profile in the treatment of glioblastoma multiforme (GBM) patients who progressed on temozolomide. Given the addition of this potent new treatment agent into the glioma arsenal, and the introduction of a new class of treatment medications it represents; it will be useful to review its clinical history and compare and contrast the experience and pitfalls other oncology sub-specialties have had with this agent.

Therapeutic Transfer of DNA Encoding Adenoviral E1A†

E1A is a multifunctional adenoviral protein expressed early after infection that interferes with numerous important regulatory processes by interaction with host cell proteins or direct transcriptional activation of target genes. Although, initially identified as the adenoviral component that can cause malignant conversion of rodent cells, remarkable tumorsuppressive effects of E1A on various types of human cancer cells were observed. Gene therapeutic approaches with E1A are currently evaluated in animal models and early clinical studies. Therapeutic applications of E1A are covered by a series of patents which include the description of small variants (mini-E1A) that can be used for tumor suppression and E1A gene transfer in combination with conventional chemotherapy. In this mini review, we provide an introduction to E1A functions, summarize relevant patents, and discuss potential clinical applications of E1A gene transfer on basis of recent results of clinical and preclinical investigations.

Neurological Complications of Antiangiogenic Therapy

Since the discovery of the principles of angiogenesis and the drugs with antiangiogenic properties, the science has evolved greatly in understanding the pathophysiology of several diseases like cancer and the development of drugs that act in the cascade of mechanisms related to angiogenesis. Due to the systemic action of antiangiogenic therapy, patients may experience several side effects, among them those related to the nervous system. Several neurological complications have been described in patients treated with antiangiogenic therapy. The neurological side effect profile of the new agents is largely unknown and may include central (reversible posterior leukoencephalopathy, strokes, encephalopathy, seizures) and peripheral neurotoxicity (autonomic, sensory or sensorimotor neuropathy) depending on the specific agent. The peripheral neurotoxicity of relatively older agents such as bortezomib and thalidomide is well described and health care professionals dealing with patients treated with such medications need to be aware of these complications. Further research is necessary to understand the mechanisms and foster prevention and treatment of these neurological complications.

Molecular Diagnosis and Prognosis

Detection of DNA and RNA alterations and proteins associated with cancer are used as indicators or biomarkers for specific tumor traits that help in cancer diagnosis and patient management. Molecular diagnosis in cancer is a new discipline that incorporates genomic and proteomic information related to malignant, premalignant and normal tissues from which clinically useful cancer biomarkers are expected to be identified. The goal is to find and clinically validate biomarkers associated with cancer risk, early detection, phenotypic tumor aggressivity, tumor staging, or biomarkers associated to prognosis such as response to treatment, disease recurrence and survival. Challenges for achieving this goal arise from a need of significant economic investment, as well as a multidisciplinary approach and the inherent molecular complexity of cancer itself.

Rhabdomyosarcoma

Animal Models for Cancer

References

Application of Main Group Elements and Their Compounds in Medicine

Pharmaceutical Potential of Pyrimidines as Antiviral Agents

Chromosome X

Chromosome 15

Chromosome 14

Chromosome 13

Overview of Cancer

Chromosome 11

Chromosome 8

Chromosome 5

Biology of Cancer

Swellings of Orofacial Structures in Children

Subject Index

Heterocyclic Anti-cancer Compounds Derived from Natural Sources with their Mechanism of Action

Subject Index

Subject Index

Updates on Pediatric Hepatoblastoma

Monitoring Therapeutic Response in Cancers: A Raman Spectroscopy Approach

Chimeric Antigen Receptor (CAR) T Cell for Pediatric Solid Tumors: The Next Frontier in Cancer Treatment

MDM2-p53 Antagonists Under Clinical Evaluation: A Promising Cancer Targeted Therapy for Cancer Patients Harbouring Wild-Type TP53

Subject Index

Breast Surgery

Pediatric Malignancy

Head and Neck Surgery

Cannabinoid-based Anti-cancer Strategies: Slowly Approaching the Bedside

Pathologies of the Peritoneum, Mesentery and Diaphragm

Cytotoxicity Through Molecular Targets Involved in Apoptosis. Where Should We Further Search for Mushrooms Functionalities in Future Cancer Treatment?

Oesophageal Neoplasms

Subject Index

Pediatric Hematological Malignancies – Clinical Manifestation, Treatment and Follow-Up

Spatial Geostatistical Analysis Applied To The Barroso-Alvao Rare-Elements Pegmatite Field (Northern Portugal)

Anatomy of Intraoral Techniques

Integral-Balance Solution to Nonlinear Subdiffusion Equation

The Contrivance of General Theory of Relativity: Unification of Abraham, Einstein and Nordström’s Hybrid Theoretical Models

Clinical Trials of Curcumin, Camptothecin, Astaxanthin and Biochanin

Microtubules as Anti-Cancer Drug Targets

Infra-sellar and Nasopharyngeal Craniopharyngioma

Cancer and its Treatment: Development of Anticancer Chemotherapeutic Agents from Natural Products

Natural Products as a Unique Source of Anti- Cancer Agents

Immune System in Cancer

Tumor Resistance Mechanisms to Inhibitors Targeting the Epidermal Growth Factor Receptor– Part I: Extracellular Molecules

Other Malignant Primary Tumors of the Liver

Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis

Calixarenes in Biotechnology and Bio-Medical Research

Targeted Cancer Therapy: The Roles Played by Antibody-Drug and Antibody-Toxin Conjugates

Mechanisms of Biological Actions of Inositol and InsP6 I: Cell Survival, Proliferation and Differentiation

Experimental Cancer Regression by InsP6 & Inositol

Current and Future Medical Therapy, and the Molecular Features of Adrenocortical Cancer

Understanding Tumor Metabolism and its Potential as a Target for the Treatment of Cancer

Combination Chemotherapy: The Road to Cure

Targeting Key Signaling Pathways in Pediatric Brain Tumors

Histopathologic Features of the Lung Cancer

Myocardial Ischemia, Myocardial Infarction

Selective Cyclooxygenase-2 Inhibitors for Malignant Glioma Therapy: Molecular Targets Beyond COX-2

Advances in mTOR inhibitors

Approach to Pediatric Neck Masses

Gene Clusters, Molecular Evolution and Disease: A Speculation

Insulin-Like Growth Factor Receptor Inhibitors: Categorical Lack of Efficacy or Lack of Personalised Medicine?

Microbiology, Virology and Histopathological Sampling and Diagnosis

miRNAs in Myocardial Infarction

Stretch Yourself: Some Consent Scenarios

Bevacizumab for Malignant Gliomas: Comparative Study with Other Malignancies

Therapeutic Transfer of DNA Encoding Adenoviral E1A†

Neurological Complications of Antiangiogenic Therapy

Molecular Diagnosis and Prognosis

Mechanisms of Biological Actions of Inositol and InsP₆ I: Cell Survival, Proliferation and Differentiation

Experimental Cancer Regression by InsP₆ & Inositol